Hess David C, Borlongan Cesar V
Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA.
Expert Rev Neurother. 2008 Aug;8(8):1193-201. doi: 10.1586/14737175.8.8.1193.
Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.
基于细胞的中风治疗代表了中风治疗的第三次浪潮，它专注于恢复过程，与神经保护疗法相比，有更长的机会窗口。中风后的第一周内的早期时间窗口，为静脉注射骨髓和围产期来源的细胞提供了机会，这些细胞可以归巢到组织损伤区域并靶向脑重塑。同种异体细胞可能是最具可扩展性和商业可行性的产品。中风数月后的较晚时间窗口，可能为神经分化细胞类型的脑内移植提供机会。需要一种将基于细胞的治疗与早期临床试验以及继续专注于作用机制的临床前工作相结合的方法。
